ARTICLE | Company News
Texas Biotech deal
July 31, 1995 7:00 AM UTC
Shareholders of TXB's ImmunoPharmaceutics Inc. subsidiary will receive an additional 1.4 million shares of TXB upon achieving an undisclosed milestone with IPI's endothelin antagonist compounds. Endothelin is a vasoconstrictor. ...